Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNKSR1 | Q969H4 | 13/20 | 0.85 |
| ▸ | AKT1 | P31749 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18160878 | 0.93 | CNKSR1 (0.79) | CNKSR1AKT1SMN1; SMN2BCL2A1ALDH1A1 | |
| SCHEMBL18163763 | 0.92 | CNKSR1 (0.83) | CNKSR1AKT1PKMHSD17B10SMN1; SMN2 | |
| SCHEMBL18163744 | 0.92 | CNKSR1 (1.00) | CNKSR1AKT1PKMHSD17B10SMN1; SMN2 | |
| SCHEMBL18163741 | 0.91 | CNKSR1 (1.00) | CNKSR1AKT1PKMHSD17B10SMN1; SMN2 | |
| SCHEMBL18148025 | 0.89 | CNKSR1 (1.00) | CNKSR1AKT1PKMHSD17B10SMN1; SMN2 | |
| SCHEMBL17211656 | 0.89 | CNKSR1 (1.00) | CNKSR1AKT1PKMHSD17B10SMN1; SMN2 | |
| SCHEMBL18163743 | 0.89 | CNKSR1 (1.00) | CNKSR1AKT1PKMHSD17B10SMN1; SMN2 | |
| SCHEMBL15811564 | 0.88 | CNKSR1 (1.00) | CNKSR1AKT1PKMHSD17B10SMN1; SMN2 | |
| SCHEMBL18163767 | 0.88 | CNKSR1 (0.81) | CNKSR1AKT1PKMHSD17B10SMN1; SMN2 | |
| SCHEMBL18163773 | 0.87 | CNKSR1 (1.00) | CNKSR1AKT1PKMHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227356-B2 | Compounds, compositions and methods for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160304533-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227356-B2 | Compounds, compositions and methods for inhibiting CNKSR1 | CNKSR1, CAMKK1, CNR1 | CNKSR1 1/4885AKT1 780/4885PKM 924/4885 |
| US-20160304533-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | CNKSR1, CAMKK1, CNR1 | CNKSR1 1/4885AKT1 780/4885PKM 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.